Is Advanced Biomed Inc. (ADVB) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | 80.2% | |
| Return on Assets (ROA) | -26.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Debt-to-Equity | 7.5 |
| Current Ratio | 8.6 |
Price & Trading
| Last Close | $4.19 |
| 50-Day MA | $4.94 |
| 200-Day MA | $8.56 |
| Avg Volume | 146K |
|
52-Week Range
$3.61
| |
About Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Advanced Biomed Inc. (ADVB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Advanced Biomed Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Advanced Biomed Inc.'s debt ratio?
Advanced Biomed Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%.
What are Advanced Biomed Inc.'s key financial metrics?
Advanced Biomed Inc. has a market capitalization of $6M, trailing P/E ratio of 1.2. Return on equity stands at 80.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.